Walter

Understanding the Impact of COVID-19 on Cardiovascular Disease

Retrieved on: 
Monday, June 12, 2023
San Francisco, Obesity, University, American Heart Association, Stress, Stroke, Moyamoya disease, COVID-19, Cardiovascular disease, Health equity, Study, Medicine, CVD, Inflammation, CDC, Hypertension, System, Death, UCSF, FAHA, Microsoft family features, Walter, Tourism, Pharmaceutical industry, Cardiology

"That this likely translated to an increase in overall cardiovascular deaths, while disheartening, is not surprising.

Key Points: 
  • "That this likely translated to an increase in overall cardiovascular deaths, while disheartening, is not surprising.
  • "COVID-19 has both direct and indirect impacts on cardiovascular health.
  • This resulted in people presenting with more advanced stages of cardiovascular conditions and needing more acute or urgent treatment for what may have been manageable chronic conditions.
  • "Additionally, there are socioeconomic considerations, as well as the ongoing impact of structural racism on multiple factors, including limiting the ability to access quality health care."

Qualtrics Announces New Designations to Improve How Governments Manage Customer and Employee Experience

Retrieved on: 
Wednesday, June 7, 2023
Technology, Other Defense, Security, Professional Services, Internet, Data Analytics, Data Management, Artificial Intelligence, Defense, Acceleration, FAR, Walter E. Washington Convention Center, United States Department of Defense, Data collection, Privacy, Government, Certification, XM, Local government, Federal Acquisition Regulation, DFARS, Washington Convention Center, Walter, Artificial intelligence, Qualtrics, Digital, FedRAMP, TSM, AWS, News, Cryptocurrency, Medical device

This announcement was made at the AWS Summit Washington, DC taking place June 7-8 at the Walter E. Washington Convention Center.

Key Points: 
  • This announcement was made at the AWS Summit Washington, DC taking place June 7-8 at the Walter E. Washington Convention Center.
  • In addition, Qualtrics is the first experience management provider to be accepted into the US Department of Defense Tradewind Solutions Marketplace as a vetted provider of technology solutions for federal agencies.
  • In achieving StateRAMP certification, Qualtrics demonstrates its dedication to providing state and local government customers with the highest level of cybersecurity protection possible.
  • State and local government data and processing will be migrated to Gov1, a Qualtrics StateRAMP authorized data center powered by AWS.

Florida Realtors® Wins 2023 ASAE Gold Circle Award for Florida Realtor® Magazine

Retrieved on: 
Wednesday, June 7, 2023
Zipper, Gold Circle, Partnership, CAE, Newsroom, American Society of Association Executives, MMCC, Marketing, Walter E. Washington Convention Center, Communication, Human, Real estate agent, Research, Creativity, Organization, Washington Convention Center, Walter, Association of American Veterinary Medical Colleges, Graphic Communications Conference, Growth, ASAE, Society, Conference, Real estate, Property management

ORLANDO, Fla., June 7, 2023 /PRNewswire/ -- Florida Realtors® announces that Florida Realtor® magazine has won a prestigious 2023 Gold Circle Award from ASAE (American Society of Association Executives) in the print magazine category.

Key Points: 
  • ORLANDO, Fla., June 7, 2023 /PRNewswire/ -- Florida Realtors® announces that Florida Realtor® magazine has won a prestigious 2023 Gold Circle Award from ASAE (American Society of Association Executives) in the print magazine category.
  • "Being named a Gold Circle Award winner is an incredible honor – these awards from ASAE are highly regarded and a pinnacle of achievement for associations," said Florida Realtors CEO Margy Grant.
  • Entries for the Gold Circle Awards competition are judged on criteria established by the ASAE Gold Circle Award Committee for excellence in association marketing, membership, and communications programs.
  • "I am thrilled to extend my congratulations to the winners of the 2023 ASAE Gold Circle Awards," said Diana Dabdub, CAE, director of admissions and recruitment affairs at the American Association of Veterinary Medical Colleges and chair of the ASAE Gold Circle Awards Committee.

OneKey® MLS CEO Richard Haggerty Inducted into National Association of Realtors' RPAC Hall of Fame

Retrieved on: 
Wednesday, May 17, 2023
MLS, Haggerty, NAR, Washington Convention Center, Walter, National Association, Real estate

NEW YORK, May 17, 2023 /PRNewswire/ -- Richard Haggerty, CEO of OneKey® MLS, the largest multiple listing service in New York, has been inducted into the National Association of Realtors Political Action Committee (RPAC) Hall of Fame.

Key Points: 
  • NEW YORK, May 17, 2023 /PRNewswire/ -- Richard Haggerty, CEO of OneKey® MLS, the largest multiple listing service in New York, has been inducted into the National Association of Realtors Political Action Committee (RPAC) Hall of Fame.
  • A highly regarded real estate leader, Haggerty has a long list of accomplishments that have been well-earned over his 38 years in the industry.
  • At the top of this list is spearheading the merger and formation of OneKey®, the first metro area regional MLS.
  • Haggerty is the former CEO of the Hudson Gateway Association of Realtors, Inc. (HGAR), a position he held since 2012.

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Retrieved on: 
Monday, May 15, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, CITES, Therapy, DC, NK, Perforin-1, Journal of Immunology, T, Walter, Poster, Cytokine, Gene, Pharmaceutical industry, Vaccine, Extractive metallurgy

The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, May 11 – 15.

Key Points: 
  • The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, May 11 – 15.
  • “Equillium is developing EQ102 to selectively and synergistically block both IL-15 and IL-21 signaling, without affecting other gamma chain family members.
  • EQ102 is a multi-cytokine inhibitor that selectively blocks IL-15 and IL-21 signaling while preserving signaling of other γc family members.
  • Similarly, in pre-clinical studies, EQ102 has demonstrated the prevention of intestinal tissue damage in a humanized mouse model of gastrointestinal inflammation.

Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International Conference

Retrieved on: 
Thursday, May 11, 2023
Inflammation, PAH, ATS, Infection, RIS, CMAX, Lung, Washington Marriott Marquis, American Thoracic Society, International Conference on Nuclear Disarmament, Oslo, 2008, MD, Washington Convention Center, Walter, Orthostatic hypertension, Pulmonary hypertension, Therapy, Conference, Pharmaceutical industry

These results, presented by Aerami Chief Medical Officer Gary Burgess, MD, demonstrate the potential to achieve therapeutic lung levels with low inhaled doses of AER-901.

Key Points: 
  • These results, presented by Aerami Chief Medical Officer Gary Burgess, MD, demonstrate the potential to achieve therapeutic lung levels with low inhaled doses of AER-901.
  • AER-901 is entering Phase 2 clinical development for two serious and rare forms of pulmonary hypertension – pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
  • The presentation will take place during the “Showcase Four: Inflammation, Infectious Disease and Other Innovators” session at 2pm EST on May 20.
  • For more information about the ATS International Conference, please visit https://conference.thoracic.org/ .

Sisu Pharma Welcomes Renowned Prostate Cancer Drug Developer Professor Michael Jung to its Scientific Advisory Board

Retrieved on: 
Thursday, April 20, 2023
Pharma, Drug development, University, Prostate cancer, Coronavirus Scientific Advisory Board, Science, Biochemistry, National academy, HSF1, Invention, National Academy of Inventors, Walter, Drug discovery, UCLA, FDA, Disease, Pharmaceutical industry, Sisu, Chemistry

SAN DIEGO, April 20, 2023 /PRNewswire-PRWeb/ -- Sisu Pharma, a biotech company exploiting cellular stress to treat therapy-resistant cancers, is delighted to announce that Professor Michael Jung has joined its Scientific Advisory Board. A highly accomplished scientist and scholar, Professor Jung brings a wealth of experience in medicinal chemistry and drug discovery to the Sisu team, with a particular focus on prostate cancer drug development. He is the inventor of both Xtandi and Erleada, FDA approved small molecule therapies that revolutionized the treatment of castration-resistant prostate cancer, an especially lethal form of the disease.

Key Points: 
  • A highly accomplished scientist and scholar, Professor Jung brings a wealth of experience in medicinal chemistry and drug discovery to the Sisu team, with a particular focus on prostate cancer drug development.
  • "I am excited to be part of Sisu Pharma's Scientific Advisory Board and to collaborate with their talented team," said Professor Jung.
  • As a member of the Scientific Advisory Board, Professor Jung will provide strategic guidance and counsel to Sisu Pharma's research and development team.
  • "We are thrilled to welcome Professor Jung to our Scientific Advisory Board", said Sean O'Brien, CEO of Sisu Pharma.

Barings Provides Financing on Courtyard/Residence Inn By Marriott Washington Downtown Convention Center

Retrieved on: 
Wednesday, April 19, 2023
Professional Services, Commercial Building & Real Estate, Lodging, Finance, Construction & Property, Asset Management, Travel, Quadrangle Development Corporation, Walter, Capstone Development, Marriott Hotels & Resorts, Hotel, Convention center, Washington Convention Center, Walter E. Washington Convention Center, Barings LLC

Barings, one of the world’s leading investment managers, announced today that it has provided a $101.5 million bridge loan to refinance the existing construction loan on the Courtyard/Residence Inn By Marriott Washington Downtown Convention Center (“the Hotel”).

Key Points: 
  • Barings, one of the world’s leading investment managers, announced today that it has provided a $101.5 million bridge loan to refinance the existing construction loan on the Courtyard/Residence Inn By Marriott Washington Downtown Convention Center (“the Hotel”).
  • Located in downtown DC across the street from the Walter E. Washington Convention Center, the Hotel is a select-service dual branded Marriott Hotel developed by Quadrangle Development Corporation and Capstone Development, LLC.
  • The 11-story hotel opened in November 2018 and contains 504 rooms outfitted with modern amenities.
  • “Quadrangle is a leading full-service real estate developer and investor in the Washington, DC area, and we are excited to be partnering with them on this high-quality asset that is already exhibiting accelerated operational performance,” said Lisa Katz, Managing Director with Barings.

Celiac Disease Foundation Announces 2023 Global Celiac Disease Research Prize Laureates

Retrieved on: 
Monday, April 17, 2023
Health, Genetics, Other Science, General Health, Research, Science, Prevalence, DRS, Doctor of Philosophy, Intestinal villus, Patient, Risk, MMSc, University of Oxford, Gastrointestinal disease, University, MB, Pediatrics, The Writing on the Wall, Mass, Map, Biomarker, Immunotherapy, Vitamin A, Mackay Base Hospital, Autoimmune disease, Cancer, Partnership, Drug development, Malnutrition, Coeliac disease, Quality of life, Inflammation, Harvard Medical School, Vaccine, Walter, Treatment, International Society, Dentistry, Gastroenterology

The Celiac Disease Foundation is proud to announce the recipients of the 2023 Global Celiac Disease Research Prizes , recognizing outstanding achievements in advancing research and treatment for celiac disease on a global scale.

Key Points: 
  • The Celiac Disease Foundation is proud to announce the recipients of the 2023 Global Celiac Disease Research Prizes , recognizing outstanding achievements in advancing research and treatment for celiac disease on a global scale.
  • The $25,000 Prize for Excellence in Celiac Disease Research, this year awarded to Dr. Robert Anderson, recognizes an investigator whose research has made a significant impact on clinical, translational, or transformative research in celiac disease.
  • “We hope that these prizes will not only recognize their achievements but also encourage continued global progress and collaboration in the field of celiac disease research.”
    Robert (Bob) Anderson, MB ChB, Ph.D., is the recipient of the Celiac Disease Foundation Prize for Excellence in Celiac Disease Research.
  • The Celiac Disease Foundation thanks our 2023 Global Celiac Disease Research Prize sponsors: Anokion and Immundiagnostik, Inc.
    Celiac disease is a complex genetic autoimmune disorder that affects an estimated 1 in 100 people worldwide.

EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases

Retrieved on: 
Monday, April 3, 2023
Vaccine, GMP, Human, Epstein–Barr virus, Genetics, Lymphoproliferative disorders, EBV, CSO, ME/CFS, Immunity, EST, CMO, Multiple sclerosis, Incidence, Infectious mononucleosis, Chronic fatigue syndrome, DSM-IV codes, PTLD, Immune system, Cancer, Walter, Washington Convention Center, Virus-like particle, Convention center, Disease

The presentation will take place on Wednesday, April 5, 2023, at 2:55 p.m. EST in Room 201 of the

Key Points: 
  • The presentation will take place on Wednesday, April 5, 2023, at 2:55 p.m. EST in Room 201 of the
    Walter E. Washington Convention Center in Washington, DC.
  • The first candidate, named EBV-001, is based on non-infectious EBV-derived virus-like particles (VLPs).
  • EBViously has generated positive preclinical proof-of-concept data on the immunogenicity of the vaccine candidate.
  • As infectious mononucleosis is a known risk factor for multiple sclerosis, there is great hope that our vaccine may also reduce the incidence of this chronic neurodegenerative autoimmune disease.”